^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Empliciti (elotuzumab)

    i
    Other names: BMS-901608, HuLuc63, PDL063, BMS901608, BMS 901608, HuLuc-63, PDL 036, PDL-063
    Company:
    AbbVie, BMS
    Drug class:
    CS-1 inhibitor
    Related drugs:
    4d
    The Anti-SLAMF7 Antibody, Elotuzumab, Induces Antibody-Dependent Cellular Cytotoxicity Against CLL Cell Lines. (PubMed, Molecules)
    ADCC was assessed by flow cytometry using E (100 μg/mL), rituximab (R, 100 μg/mL), and their combination (E + R). The combination of E + R showed no significant synergy over monotherapies. In conclusion, elotuzumab induced significant ADCC in CLL cells, warranting further therapeutic evaluation.
    Preclinical • Journal • IO biomarker
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Rituxan (rituximab) • Empliciti (elotuzumab)
    14d
    Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov)
    P1, N=27, Recruiting, Abdullah Khan | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • mezigdomide (CC-92480) • dexamethasone injection
    18d
    A Multicentre Phase 3 Trial Comparing Elotuzumab-Cyclophosphamide-Thalidomide-Dexamethasone (E-CTD) with Cyclophosphamide-Thalidomide-Dexamethasone (CTD) for the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM) (ACTRN12616001030460)
    P3, N=300, Active, not recruiting, Australasian Leukaemia and Lymphoma Group (ALLG) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • thalidomide • Empliciti (elotuzumab)
    24d
    A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • pomalidomide • Empliciti (elotuzumab)
    1m
    Elo-KRd: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Completed, University of Chicago | Trial completion date: Mar 2027 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    lenalidomide • carfilzomib • dexamethasone • Empliciti (elotuzumab)
    1m
    A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • Empliciti (elotuzumab) • iberdomide (CC-220)
    2ms
    Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    JAK2 (Janus kinase 2)
    |
    Empliciti (elotuzumab)
    2ms
    XPORT-MM-031: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma (clinicaltrials.gov)
    P3, N=117, Active, not recruiting, European Myeloma Network B.V. | Recruiting --> Active, not recruiting | N=222 --> 117
    Enrollment closed • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • Empliciti (elotuzumab)
    3ms
    SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma. (PubMed, Cancers (Basel))
    The target has a proven clinical success with Elotuzumab (anti-SLAMF7 antibody); it works by activating immune cells to kill myeloma cells, and limited expression on normal tissues, with, potentially, few side effects...However, 'fratricide death', a phenomenon where the engineered CAR-T cells attack and kill each other, is a critical issue that requires safe engineering solutions. In this work, we will provide an overview on the field with a specific focus on SLAMF7 as an emerging CAR-T cell target in MM.
    Review • Journal • IO biomarker
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Empliciti (elotuzumab)
    4ms
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2027 --> Jan 2028
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    4ms
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2030 --> Jun 2027
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    5ms
    Elo-KRd: Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, University of Chicago | Trial completion date: Mar 2029 --> Mar 2027
    Trial completion date
    |
    lenalidomide • carfilzomib • dexamethasone • Empliciti (elotuzumab)